WebWire
Future Fields, the protein biomanufacturing company behind the world’s first Drosophila-based EntoEngine™ platform and Instar biofactory, today announced the close of its Series A funding round to expand the company’s commercial traction across agriculture, food, and biopharma markets. The $8.0 million USD oversubscribed round was co-led by Amplify Capital…
Read More
Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases and Unlock the AI Bio-revolution
Yuri Grisby
18:21
Future Fields, the protein biomanufacturing company behind the world’s first Drosophila-based EntoEngine™ platform and Instar biofactory, today announced the close of its Series A funding round to expand the company’s commercial traction across agriculture, food, and biopharma markets. The $8.0 million USD oversubscribed round was co-led by Amplify Capital…
